Laboratory News and Research

RSS

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Heart failure is by far the most prevalent chronic cardiac condition. Around 30 million people in Europe have heart failure and its incidence is still increasing: more cases are being identified, more people are living to an old age, and more are surviving a heart attack but with damage to the heart muscle.

2 Mar 2010

Discovery of two new compounds opens new approach to drug design against HIV protease

A team of researchers at the renowned Scripps Research Institute has discovered two new compounds that prove the existence of new binding sites on HIV protease. Associate Professor C. David Stout, senior author of the study, explained "These results open the door to a whole new approach to drug design against HIV protease," which is an enzyme used by HIV to create new, infectious viral particles.

2 Mar 2010

Future work may uncover links between insulin use and cancer risk, say researchers

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

2 Mar 2010

InterSystems Ensemble platform enables first successful electronic transmission of genetic data

InterSystems Corporation, the global leader in software for connected healthcare, today announced that InterSystems Ensemble® was the software platform for the first-ever successful electronic transmission of comprehensive genetic data. The information was sent cross-country from Boston-based Partners HealthCare Center for Personalized Genetic Medicine (PCPGM) to Intermountain HealthCare in Salt Lake City, Utah. The announcement about reaching this milestone in personalized medicine came at the HIMSS10 conference.

2 Mar 2010

GenWay Biotech's simple blood sample cancer assessment test

San Diego-based GenWay Biotech, Inc. today announced the availability of the You Test You- Cancer Assessment that allows patients to test for various types of cancer without having to visit their doctor's office, through a simple blood sample. With a 10-day turnaround time and a cost of $149, You Test You- is a convenient and low cost way to periodically test for indication of cancer.

2 Mar 2010

ZyGEM introduces new RNAGEM Tissue RNA extraction kits

ZyGEM Corp. Ltd., a provider of innovative enzyme-based products for DNA and RNA extraction and other life sciences applications, today announced the launch of its new RNAGEM™ Tissue RNA extraction kits. This product represents a significant advance in sample preparation for RNA-based testing and analysis.

2 Mar 2010

WuXi PharmaTech, JANSSEN division announce collaboration for preclinical services

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.

2 Mar 2010

News outlets examine development of low-cost diagnostic tool, infectious disease surveillance

CNN examines the work of a Harvard University chemistry professor to "shrink a medical laboratory onto a piece of paper that's the size of a fingerprint and costs about a penny." According to George Whitesides, who created a prototype of the inexpensive paper "chip," the technology could be used to diagnose such diseases as HIV, malaria and tuberculosis in developing countries.

2 Mar 2010

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

Agilent Technologies Inc. today introduced the 5975T Low Thermal Mass (LTM) Gas Chromatography/Mass Spectrometry Detector (GC/MSD), the industry’s first commercial transportable GC/MS system that delivers laboratory-quality analysis. Using proprietary LTM technology, Agilent has developed the 5975T LTM GC/MS to be smaller, more rugged and to consume less power than in-lab GC/MS instruments, yet capable of the same high-quality performance in the field.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

Study results of new PCR technology that reports mutations associated with FXS announced

Asuragen, Inc. announced today the results of a collaborative study with scientists at the M.I.N.D. Institute at the University of California Davis evaluating a new PCR technology that reproducibly reports mutations associated with Fragile X syndrome (FXS).

2 Mar 2010

There are many obstacles to diagnosing and treating HAE, says expert

There are many obstacles to diagnosing and effectively treating hereditary angioedema (HAE). Symptoms of HAE are often indistinguishable from other conditions and accurate diagnosis requires both detailed patient and family history, as well as a combination of laboratory tests.

2 Mar 2010

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Agilent’s major new lab informatics suite, the OpenLAB portfolio, is designed to enable customers to easily capture, analyze and share scientific data throughout the lab and across the enterprise. OpenLAB is scalable, open architecture based on industry open standards.

2 Mar 2010

Gene research offers new hope for targeted breast cancer treatment

CANCER RESEARCH UK scientists have developed a system to identify faulty or missing genes that could prevent specific chemotherapy regimes from working. This opens the doors for targeted breast cancer treatment, according to research published in the Lancet Oncology* today (Monday).

2 Mar 2010

Oxidative stress could lead to health problems and premature death

If you aren't getting a good, consistent and regular night's sleep, a new study suggests it could reduce your ability to handle oxidative stress, cause impacts to your health, increase motor and neurological deterioration, speed aging and ultimately cut short your life.

2 Mar 2010

New treatment guidelines demonstrate that best care does not always cost more

Arizona Oncology is proud to be a part of the larger network that just completed a recently conducted study by US Oncology and Aetna that finds evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes.

2 Mar 2010

Olympus America signs nonexclusive worldwide licensing agreement with Omnyx

Olympus America Inc. has signed a nonexclusive worldwide licensing agreement with Omnyx, LLC, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, allowing Omnyx to access an extensive portfolio of Olympus America patents in the field of virtual microscopy and digital pathology, to help develop solutions in the digital pathology field.

From Evident Corporation - Life Sciences 1 Mar 2010

4medica's IHR to be demonstrated at HIMSS conference

4medica, the leading independent provider of Web-based connectivity between physicians and clinical laboratories, today announced the launch of its Integrated Health Record (IHR™), which includes modular components designed to enable hospitals and eligible providers to demonstrate “meaningful use” and qualify for federal government incentives in 2011.

1 Mar 2010

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

In a study published in the March 2010 issue of The American Journal of Medicine, researchers determined that regular use of aspirin, acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) increases the risk of hearing loss in men, particularly in younger men, below age 60.

1 Mar 2010

Merck to acquire Millipore for US$ 107 per share in cash

Merck KGaA, a global pharmaceutical and chemical company, and Millipore Corporation, a leading Life Science company based in Billerica, Massachusetts, USA, today announced that they have entered into a definitive agreement under which Merck KGaA will acquire all outstanding shares of common stock of Millipore, for US$ 107 per share in cash, or a total transaction value, including net debt, of approximately EUR 5.3 billion (US$ 7.2 billion).

28 Feb 2010

Laboratory News and Research

Critical follow-up evaluations provide opportunity to help physicians best evaluate their HF patients

Discovery of two new compounds opens new approach to drug design against HIV protease

Future work may uncover links between insulin use and cancer risk, say researchers

InterSystems Ensemble platform enables first successful electronic transmission of genetic data

GenWay Biotech's simple blood sample cancer assessment test

ZyGEM introduces new RNAGEM Tissue RNA extraction kits

WuXi PharmaTech, JANSSEN division announce collaboration for preclinical services

News outlets examine development of low-cost diagnostic tool, infectious disease surveillance

Agilent Technologies launches industry’s first transportable GC/MS system delivering laboratory-quality analysis

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

Study results of new PCR technology that reports mutations associated with FXS announced

There are many obstacles to diagnosing and treating HAE, says expert

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Gene research offers new hope for targeted breast cancer treatment

Oxidative stress could lead to health problems and premature death

New treatment guidelines demonstrate that best care does not always cost more

Olympus America signs nonexclusive worldwide licensing agreement with Omnyx

4medica's IHR to be demonstrated at HIMSS conference

Regular use of aspirin, acetaminophen and NSAIDs increases risk of hearing loss in men

Merck to acquire Millipore for US$ 107 per share in cash

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo